Active Systemic Lupus Erythematosus Clinical Trial
Official title:
A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy
The primary objective is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04931563 -
Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
|
Phase 3 | |
| Completed |
NCT02446912 -
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
|
Phase 3 | |
| Completed |
NCT02794285 -
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
|
Phase 3 | |
| Completed |
NCT02446899 -
Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
|
Phase 3 |